PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU

WALTHAM, Mass., Dec. 17, 2018 -- (Healthcare Sales & Marketing Network) -- PharmaEssentia, a global biopharmaceutical company focused on developing and commercializing novel treatments for treatment of rare diseases, today announced that the Committee for... Biopharmaceuticals, Regulatory PharmaEssentia, Besremi , polycythaemia vera
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news